Alpha-1-antitrypsin subcutaneous - Precigen Inc
Alternative Names: recombinant human alpha-1-antitrypsin - Precigen Inc; rHuA1AT - Precigen IncLatest Information Update: 24 Nov 2021
Price :
$50 *
At a glance
- Originator Intrexon Corporation
- Developer Precigen Inc
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Enzymes; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (SC, Injection)
- 06 Jun 2011 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (SC)